<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190901044665N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-10-30</date_registration>
      <primary_sponsor>Ardabil University of Medical Sciences</primary_sponsor>
      <public_title>Comparison Between Sublingual Buprenorphine and Fentanyl  Intravenous Pump for Postoprative Pain  Relief  After Open Cholecystectomy Surgery.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison Between Sublingual Buprenorphine and Fentanyl  Intravenous Pump for Postoprative Pain  Relief  After Open Cholecystectomy Surgery.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/41901</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Single, Purpose: Treatment, Randomization description: After  patients were allowed to enter the study 80 patients were selected using simple sampling and the selected patients will be divided into two groups by random block design with 4 blocks. In this case all possible modes were considered to accommodate the  letters AABB which is 6 modes.  These 6cases were  embedded in 6 papers and the papers were  embedded in a black bag. Then we will make 20 paper bags every time. We draw a piece of paper write down the letters in it and we will add the  next letter in the next drawing followed by the previous note we will have 80 letters in the end and at the time of sampling each person will receive a special letter in order of entry  into the sample and so the people feel into one group , Blinding description: The first group of 40 patients receiving Sublingual Buprenorphine Tablet and intravenous placebo Pump The second group will consist of 40 patients receiving Sublingual  placebo Tablet  and intravenous  Fentanyl  Pump. All Patients will be anesthetized  by  one-way treatment  Protocol. Given that the study is randomly blocked,Buprenorphine and Placebo  Buprenorphine and Fntanyl Pump and placebo pump separately and in two packs (Containing one pump and one Tablet) with specific codes B and A (Pack A containing Sublingual Buprenorphine and Placebo Pumps and and Pack B containing Placebo Tablets and Fentanyl Pumps) and  The drug injector (Anesthetic Technician) has no information about the contents of the pack Select Pack A or B based on the Patient group.  already specified  are provided and every morning before the operation the number of  Surgeries will be eliminated the same day.Start prescribing housing content envelopes after complete Cholecystectomy And it will be done in recovery.  Patients will not be informed about the type of drug they receive.</study_design>
      <phase>3</phase>
      <hc_freetext>Comparison between Sublingual Buprenorphine and Fentanyl Intravenous Pump for postoperative pain relief after open Cholecystectomy Surgery.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group, Sublingual Buprenorphine Tablet administered 0.4 mg in 6, 12 and 18 hours recovey  and Placebo Pump 50 cc normal saline in recovery and continued for 24 hours, if pain is not controlled, PCA is injected every 15 minutes. Intervention 2: Control group:In the control group, Placebo Tablets were administered at 6,12 and 18 h,50 cc intravenous Fentanyl Pump (40 cc Fentanyl and 10 cc normal saline) embedded and half a cc (20 micrograms) of stat is injected and if the pain is not controlled, PCA is given  by the patient.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Due to Ethical Problems and Patient safety, The publish of IPD not applicable.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ahmad Ghazi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Reza Hospital , Basij Square</address>
        <city>Ardabil</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5618985991</zip>
        <telephone>009844838649</telephone>
        <email>dr.ghaziahmad@gmail.com</email>
        <affiliation>Ardabil University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ahmad Ghazi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Reza Hospital,  Basij square</address>
        <city>Ardabil</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5618985991</zip>
        <telephone>+98 914 151 5271</telephone>
        <email>dr.ghaziahmad@gmail.com</email>
        <affiliation>Ardabil University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients undergoing open cholecystectomy
Patients ASA 1and2
Patients who have no further surgery
Age range 20 to 50 years</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of opium use
Nervous drug history
Active asthma
ASA3
Other concurrent surgery
Surgery lasted
Complicated surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group, Sublingual Buprenorphine Tablet administered 0.4 mg in 6, 12 and 18 hours recovey  and Placebo Pump 50 cc normal saline in recovery and continued for 24 hours, if pain is not controlled, PCA is injected every 15 minutes.</i_keyword>
      <i_keyword>Control group:In the control group, Placebo Tablets were administered at 6,12 and 18 h,50 cc intravenous Fentanyl Pump (40 cc Fentanyl and 10 cc normal saline) embedded and half a cc (20 micrograms) of stat is injected and if the pain is not controlled, PCA is given  by the patient.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Reduction of pain after open Cholecystectomy. Timepoint: VRS score(Verbal Rating Score) in both groups at the time of study (in recovery,2,6,12,18 and 24) will be evaluated. Method of measurement: Through the Score Verbal Rating Scale (VRS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Nausea and Vomiting Score after open Cholecystectomy. Timepoint: Nausea and Vomiting in both groups at the time of study (in recovery,2,6,12,18 and 24) will be evaluated. Method of measurement: By Scoring N&amp;V Score.</sec_outcome>
      <sec_outcome>Sedation Score after open Cholecystectomy. Timepoint: Sedation Score(Through the Ramsay relaxation Scale) in both groups at the time of study (in recovery,2,6,12,18 and 24) will be evaluated. Method of measurement: Through the Ramsay relaxation Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ardabil University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-06-09</approval_date>
        <contact_name>Ethics committee of Ardabil University of Medical Sciences</contact_name>
        <contact_address>Ardebil University of Medical Sciences,  Office Complex End of University  Street Ardabil Ardabil Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
